Sm-logo-resized.jpg.png
Recombinant DNA Technology is expected to reach a valuation of USD 1.378 trillion by 2030.
07 juil. 2022 14h36 HE | STRATEGIC MARKET RESEARCH LLP
New York, United States, July 07, 2022 (GLOBE NEWSWIRE) -- The factors accelerating the market’s growth are high investments in Research and Development, the quick adoption of the genetically...
Rich Pharma logo.png
Rich Pharmaceuticals' Study Drug RP-323 (TPA) is a Potential Therapeutic Agent for the Treatment of Hodgkin's Lymphoma
14 mars 2018 09h45 HE | Rich Pharmaceuticals
BEVERLY HILLS, CA , March 14, 2018 (GLOBE NEWSWIRE) -- Rich Pharmaceuticals, Inc. (OTC: RCHA), a Biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology,...
ClearPoint-13169-Final-Logo-CMYK jpg.jpg
MRI Interventions' ClearPoint(R) System Helps Advance Brain Cancer Clinical Trial of Investigational Gene Therapy Drug Toca 511, Demonstrates Benefits of MRI-Guided Drug Delivery
25 avr. 2013 08h00 HE | ClearPoint Neuro, Inc.
IRVINE, Calif., April 25, 2013 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) today announced that its ClearPoint® Neuro Intervention System is advancing the minimally-invasive...